Abstract
Summary Newborn screening for phenylketonuria has been available since the early 1960s. Advances in technology such as the introduction of tandem mass spectrometry have increased the number of conditions we are now able to screen for. More recently the possibility of genetic profiling of the newborn has been raised. This article looks at these changes and discusses some of the ethical issues that they raise.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
